What Is BPC-157? Research Overview, Mechanisms, and Study Design.

BPC-157 is a synthetic pentadecapeptide, a 15 amino acid chain derived from a partial sequence of a protein found in human gastric juice. In the published literature it is studied as a laboratory compound in cell culture and animal models, primarily for how it modulates angiogenesis and the nitric oxide system. The compound is not approved by the FDA for any use, and the material described here is for in vitro research use only.

What is the structure and origin of BPC-157?

BPC-157, sometimes written as Body Protection Compound 157, is described in the literature as a stable gastric pentadecapeptide. It is a synthetic fragment corresponding to a partial sequence of a protein identified in human gastric juice, with the reported amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The peptide was first characterized in the early 1990s by Sikiric, Seiwerth and colleagues at the University of Zagreb, who have authored much of the foundational work. A recurring point of research interest is its reported stability in low-pH conditions such as gastric juice, an environment in which many peptides degrade rapidly. This relative resistance to acidic breakdown is one reason it has been examined across so many experimental models (Sikiric et al., 2025).

What mechanisms of BPC-157 have been studied?

The most extensively documented mechanism in peer-reviewed research is modulation of angiogenesis, the formation of new blood vessels. Hsieh and colleagues (2017) reported that BPC-157 was associated with upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and activation of the downstream Akt-eNOS signaling pathway. In their work, BPC-157 promoted VEGFR2 internalization in vascular endothelial cells, an effect blocked by the endocytosis inhibitor dynasore. Using a chick chorioallantoic membrane assay and an endothelial tube formation assay, the authors observed increased vessel density both in vivo and in vitro. Notably, the in vitro human endothelial cell work indicated increased VEGFR2 expression rather than increased VEGF-A itself, pointing to a receptor-level effect (Hsieh et al., 2017).

How does BPC-157 interact with the growth hormone receptor?

A separate line of study examined the growth hormone receptor in connective tissue cells. Chang and colleagues (2014) isolated tendon fibroblasts from rat Achilles tendon and treated cultured cells with BPC-157. They reported that the growth hormone receptor was among the most strongly upregulated genes, and that BPC-157 increased growth hormone receptor expression at both the mRNA and protein levels in a dose- and time-dependent manner. An earlier in vitro study by the same group (Chang et al., 2011) reported that BPC-157 was associated with tendon explant outgrowth, cell survival, and cell migration. Together these cell-culture findings are frequently cited as mechanistic context for the peptide's study in tissue-pathway research. They remain laboratory observations, not demonstrations of any clinical outcome.

What role does the nitric oxide system play?

BPC-157 is repeatedly described as interacting with the nitric oxide (NO) system, a pathway that governs vascular tone and endothelial function. A 2025 synthesis by Sikiric and colleagues in the journal Pharmaceuticals frames the peptide as a modulator of angiogenesis that operates through the NO system, and links its reported endothelial effects to nitric oxide synthase activity. This review positions the VEGFR2 pathway and the NO pathway as overlapping mechanisms studied in the literature. Because a review aggregates many underlying animal and cell studies rather than reporting a single new experiment, it is useful for understanding the proposed mechanistic picture, while the individual primary studies remain the source of specific experimental results (Sikiric et al., 2025).

What study designs are used in BPC-157 research?

The BPC-157 literature is built on two main study types. The first is in vitro cell culture, such as the tendon fibroblast and endothelial cell experiments above, where isolated cells are exposed to the peptide and molecular endpoints like receptor expression are measured. The second is in vivo rodent models, typically rats, used to study wound, muscle, and tendon healing endpoints through methods such as immunohistochemistry and laser Doppler blood-flow imaging (Brcic et al., 2009). These designs let researchers isolate mechanisms under controlled conditions. They do not, on their own, establish effects in humans, and results from animal models do not transfer directly to people.

Are there human clinical trials of BPC-157?

This is the most important context for reading any BPC-157 claim. Despite a large preclinical body of work spanning three decades, published human clinical data is extremely limited, and a 2025 systematic review of orthopaedic sports medicine use found that the evidence base remains predominantly preclinical (Vasireddi et al., 2025). BPC-157 has not been approved by the FDA or comparable regulators for any indication. For that reason, BPC-157 sold by research suppliers, including Next Level Labs, is offered strictly for in vitro laboratory and research use only. It is not for human consumption and is not intended to diagnose, treat, cure, or prevent any condition.

Where can researchers find related materials?

BPC-157 appears in NLL's tissue-repair research category, including the Wolverine Stack, a research blend referenced in literature on angiogenesis and extracellular matrix pathways. Independent third-party purity data for each lot is published in the Lab Reports library, and common questions about research-use framing are answered on the FAQ page. For the broader category, see the tissue repair pathway research overview.

For in vitro research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any condition. This article summarizes published research and is not medical advice.